Form 4 for KROS Keros Therapeutics, Inc.
Accepted 2025-09-05 00:00:00 ET · period of report 2025-09-03 · accession 0001415889-25-023791 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-09-05 | 2025-09-03 | KROS | Seehra Jasbir | CEO, Dir | A - Grant | $0.00 | +90.5K | 392.7K | +30% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-09-03 | A | A | 90,500 | $0.00 | 392,723 | D | — | — | (F1) Represents a restricted stock unit ("RSU") award. The RSUs vest as follows: 25% of the RSUs shall vest on each of February 18, 2026, February 18, 2027, February 18, 2028 and February 18, 2029, in each case, subject to the Reporting Person continuing to provide service through each such date. |